Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Summary

The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.

Conditions

• Burkitt Lymphoma
• Non-Hodgkins Lymphoma
• Atypical Burkitt Lymphoma

Interventions

DRUG

Rituximab

Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1

DRUG

Cyclophosphamide

Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)

DRUG

Doxorubicin

Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)

DRUG

Vincristine

Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)

DRUG

Methotrexate

Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle

DRUG

Leucovorin

Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)

DRUG

Ifosfamide

High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle

DRUG

Etoposide

High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle

DRUG

Cytarabine

Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle

DRUG

Mesna

High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle

Sponsors & Collaborators

• Beth Israel Deaconess Medical Center

  collaborator OTHER

• Brigham and Women's Hospital

  collaborator OTHER

• Dana-Farber Cancer Institute

  lead OTHER

Principal Investigators

• Ann S. La Casce, MD · Dana-Farber Cancer Institute

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-07-31

Primary Completion

2009-12-31

Completion

2011-06-30

Countries

• United States

Study Locations